Survey: pols don't dent DTC credibility

Share this article:
All the fury over DTC drug ads emanating from Washington hasn't dented their credibility with consumers, according to Rodale's 11th annual Survey on Consumer Reaction to DTC Advertising of Prescription Drugs.

The survey found little to suggest a hardening in attitudes toward drug ads—despite recent congressional inquests into advertising of Vytorin and Lipitor, headline-grabbing drug safety worries and legislation aimed at curbing consumer drug advertising. The number of respondents agreeing that “drug ads are done responsibly” was down a point to 56%, while those saying “government regulations allow only the safest medicines to be advertised” was up two points to 40%. Around three-quarters of respondents continue to agree that “ads tell people about new treatments” (78%), “ads alert people to symptoms that are related to a medical condition” (77%) and “ads allow people to be more involved in their healthcare” (74%). The one blip in perceptions of ads was a seven-point jump in the number agreeing that “ads cause tension between doctors and patients” (44%).

But the proliferation of doctors—and actors playing doctors—in drug ads since 2005 may be taking some of the starch out of those lab coats. The numbers of respondents saying that doctors in ads “make no difference in believing the medicine is safe/effective” rose six and seven points, to 72% and 75%, respectively. 

“Anytime you see ‘Four out of five doctors recommend,' remember that three out of four consumers don't care,” quipped Rodale director of consumer insights, Cary Silvers, who noted that all the attention on Pfizer's Lipitor ads starring Dr. Robert Jarvik had probably taken a toll.

For the most part, the survey's numbers remained static. On an eight-year average, a third of respondents who see any DTC ads report talking to their doctor about a medicine advertised. 

The telephone survey of 1,503 adults, conducted from March 3-20, was sponsored by Rodale's Men's Health, Women's Health and Prevention magazines. 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.